摘要
新型冠状病毒感染已流行三年之久,虽然病毒的不断变异使得其致病力减弱,但伴有基础病的老年患者仍是新冠病毒重症感染的高危人群。随着对新冠病毒分子结构和致病机制的不断认识,抗新冠病毒药物相继上市,这些药物可以有效降低老年患者的重症率及死亡率。该文就目前我国附条件批准上市的5种小分子抗病毒药物的作用机制、临床用药、药物相互作用、不良反应等多方面进行阐述,为老年人抗新冠病毒治疗的临床合理用药提供参考建议。
COVID-19 has been prevalent for three years.The virulence of SARS-CoV-2 is weaken as it mutates continuously.However,elderly patients,especially those with underlying diseases,are still at high risk of developing severe infections.With the continuous study of the molecular structure and pathogenic mechanism of SARS-CoV-2,antiviral drugs for COVID-19 have been successively marketed,and these anti-SARS-CoV-2 drugs can effectively reduce the severe rate and mortality of elderly patients.This article reviews the mechanism,clinical medication regimens,drug interactions and adverse reactions of five small molecule antiviral drugs currently approved for marketing in China,so as to provide advice for the clinical rational use of anti-SARS-CoV-2 in the elderly.
作者
潘敏
张田婧
常双
冯晓霞
魏伟
李俊
赵红梅
费广鹤
李家斌
陈飞虎
戴敏
孟晓明
王华
项轶
曹孟淑
陈晓阳
叶贤伟
许杜娟
胡晓文
姜玲
王昌会
汪永忠
刘浩
谢海棠
方平
钱震东
唐超
杨刚
腾小宝
钱朝霞
丁国正
孙艳
范晓云
张玲玲
PAN Min;ZHANG Tian-jing;CHANG Shuang;FENG Xiao-xia;WEI Wei;LI Jun;ZHAO Hong-mei;FEI Guang-he;LI Jia-bin;CHEN Fei-hu;DAI Min;MENG Xiao-ming;WANG Hua;XIANG Yi;CAO Meng-shu;CHEN Xiao-yang;YE Xian-wei;XU Du-juan;HU Xiao-wen;JIANG Ling;WANG Chang-hui;WANG Yong-zhong;LIU Hao;XIE Hai-tang;FANG Ping;QIAN Zhen-dong;TANG Chao;YANG Gang;TENG Xiao-bao;QIAN Chao-xia;DING Guo-zheng;SUN Yan;FAN Xiao-yun;ZHANG Ling-ling(the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Institute of Clinical Pharmacology,Anhui Medical University,Hefei 230032,China;College of Pharmacy,Anhui Medical University,Hefei 230032 China;China-Japan Friendship Hospital,Beijing 100029,China;Anhui University of Chinese Medicine,Hefei 230012,China;Ruijin Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China;Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China;the Second Affiliated Hospital,Fujian Medical University,Quanzhou Fujian 362000,China;Guizhou Provincial People’s Hospital,Guiyang 550025,China;the First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,China;the First Affiliated Hospital,Anhui University of Chinese Medicine,Hefei 230012,China;College of Pharmacy,Bengbu Medical College,Bengbu Anhui 233000,China;the First Affiliated Hospital of Wannan Medical College,Wuhu Anhui 241001,China;Tongling People’s Hospital,Tongling Anhui 244099,China;Tongling Municipal Hospital,Tongling Anhui 244000,China;Bozhou Hospital of Traditional Chinese Medicine,Bozhou Anhui 236800,China;the Second People’s Hospital of Wuhu,Wuhu Anhui 241000,China;the Second People’s Hospital of Fuyang,Fuyang Anhui 236015,China;Bengbu Third People’s Hospital Affiliated to Bengbu Medical College,Bengbu Anhui 233000,China;Anqing Municipal Hospital,Anqing Anhui 246004,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2023年第3期425-430,共6页
Chinese Pharmacological Bulletin
基金
国家自然科学基金联合基金项目(No U1803129)。
